We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+12.33%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.23B
AUM Growth
-$160M
(-3%)
Cap. Flow
-$204M
Cap. Flow
% of AUM
-3.9%
Top 10 Holdings %
Top 10 Hldgs %
34.65%
Holding
139
New
8
Increased
26
Reduced
20
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Disc Medicine
IRON
|
+$97.9M |
| 2 |
UnitedHealth
UNH
|
+$60M |
| 3 |
Ionis Pharmaceuticals
IONS
|
+$51.5M |
| 4 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
+$37.9M |
| 5 |
Tenet Healthcare
THC
|
+$26.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
+$108M |
| 2 |
argenx
ARGX
|
+$94.8M |
| 3 |
AbbVie
ABBV
|
+$80.5M |
| 4 |
Pfizer
PFE
|
+$57.8M |
| 5 |
Guardant Health
GH
|
+$53.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.41% |
| 2 | Miscellaneous | 1.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
126
CALL
Vaxcyte
PCVX
$8.74B
| – | – |
-250,000
| Closed | -$6M |
|
127
Arcus Biosciences
RCUS
$2.99B
| – | – |
-303,000
| Closed | -$7.93M |
|
128
Vor Biopharma
VOR
$1.32B
| – | – |
-5,590
| Closed | -$445K |
|
|
LENZ
129
LENZ Therapeutics
LENZ
$134M
| – | – |
-121,202
| Closed | -$2.69M |
|
|
ACHL
130
DELISTED
Achilles Therapeutics
ACHL
| – | – |
-1,463,251
| Closed | -$3.31M |
|
|
SGEN
131
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
| – | – |
-25,000
| Closed | -$3.42M |
|
|
JNCE
132
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| – | – |
-2,928,900
| Closed | -$6.85M |
|
|
TCDA
133
DELISTED
Tricida, Inc. Common Stock
TCDA
| – | – |
-10,280,947
| Closed | -$108M |
|
|
LOGC
134
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
| – | – |
-8,466,783
| Closed | -$2.31M |
|
|
LBPH
135
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| – | – |
-113,500
| Closed | -$422K |
|
|
BHVN
136
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| – | – |
-170,769
| Closed | -$25.8M |
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q4 2022 Portfolio in Review
As of Q4 2022, OrbiMed held 139 positions worth $5.23B, down 3% from $5.39B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
OrbiMed withdrew a net $204M in Q4 2022, closing 24 positions and reducing 20 holdings. Its most notable exit was Tricida, Inc. Common Stock, an estimated $108M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous.
Against the trend, OrbiMed opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $19.5M.
- OrbiMed's largest Q4 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 171,000 shares worth $19.5M.
- OrbiMed added most to Disc Medicine in Q4 2022, an estimated $97.9M increase.
- OrbiMed's biggest Q4 2022 reduction was argenx, cutting an estimated $94.8M.
- OrbiMed fully exited Tricida, Inc. Common Stock in Q4 2022, selling an estimated $108M.
- OrbiMed's ten largest holdings make up 35% of its $5.23B portfolio in Q4 2022.
- OrbiMed opened 8 new positions and closed 24 in Q4 2022.
- OrbiMed's portfolio value fell 3% quarter-over-quarter to $5.23B.
Based on OrbiMed's 13F filing for Q4 2022, filed 14 Feb 2023.